NCT00671073

Study To Assess Efficacy and Safety of Oglemilast in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase II Dose-Ranging Study of the Efficacy and Safety of Oglemilast in Patients With COPD

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 427 (actual)
• Sponsor: Forest Laboratories · Industry
• Sex: All
• Age: 40 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study will assess the safety and efficacy of a range of oglemilast doses. The study will be 14 weeks in duration. All patients meeting the eligibility criteria will be randomized to one of three doses of oglemilast or placebo.

Conditions

• Pulmonary Disease, Chronic Obstructive

Interventions

Type	Name	Description
DRUG	Oglemilast	Oglemilast low dose, oral administration, once daily for 12 weeks
DRUG	Placebo	Placebo, oral administration, once daily for 12 weeks
DRUG	Oglemilast	Oglemilast middle dose, oral administration, once daily for 12 weeks
DRUG	Oglemilast	Oglemilast high dose, oral administration, once daily for 12 weeks

Timeline

• Start date: 2008-05-05
• Primary completion: 2009-05-15
• Completion: 2009-05-15
• First posted: 2008-05-02
• Last updated: 2019-09-19

Locations

47 sites across 1 country: United States